Kornimate/medical-research-clean huggingface dataset:
recognition of a cardiac arrest within the ems

Conditions: Cardiac Arrest

Summary: this study aims to evaluate the average time taken by the medical regulation assistants (mra) to detect a cardiac arrest during the call to the ems as well as the factors influencing this delay. its main objective is to evaluate the delay, in seconds, between the call being picked up and the recognition of a cardiac arrest by the medical regulation assistant at the ems 95

in france, the incidence of cardiac arrest in adults is approximately 40,000 per year. it is a major cause of mortality with an average survival rate of 8%, as well as morbidity, particularly neurological morbidity for surviving patients. the majority of cardiac arrests occur at in france, the incidence of cardiac arrest in adults is approximately 40,000 per year. it is a major cause of mortality with an average survival rate of 8%, as well as morbidity, particularly neurological morbidity for surviving patients. the majority of cardiac arrests occur at home, in the presence of a witness. in the event of a cardiac arrest, every minute counts. studies have shown that the time between the patient's collapse and the start of ecm (external cardiac massage) is directly correlated to the survival rate after a cardiac arrest. according to other studies, a maximum delay of 90 seconds between the call to the ems and the recognition of the cardiac arrest would be the most optimal for the patient, but is it reached at the ems 95? this study aims at evaluating the average time taken by the assistants of medical regulation (arm) to detect a cardiac arrest during the call to the ems as well as the factors influencing this delay. its main objective is to evaluate the delay, in seconds, between the call pick-up and the recognition of a cardiac arrest by the medical regulation assistant at the ems 95. this evaluation will be made in particular by determining the elements of language highlighting the cardiac arrest, those which lengthen the time of detection of the arrest and the delay of starting a procedure by the arm. the study will be conducted within the ems and will include a review of the current state of knowledge and experience of the mras. this study will be carried out within the ems 95.

Eligibility criteria:
inclusion criteria : - any call resulting in the detection of a cardiac arrest during arm regulation: calls to 15 and calls transmitted by 18 exclusion criteria : * traumatic context * call involving cardiac arrest already identified as such by the caller or 18 * call with criteria of proven death * the caller does not speak french, the linguistic elements noted are not usable.

Keywords: cardiorespiratory arrest (cra) medical regulation assistant (mra) ems external cardiac massage external automated defibrillator 90 seconds
tolerability and efficacy of adjuvant t-dm1 in patients with her2 positive breast cancer after incomplete pathological response to neoadjuvant chemotherapy including anti-her2 agents.

Conditions: Breast Cancer

Summary: multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

patients affected by will be included in the study and analyzed her2 positive breast cancer with residual invasive disease after neoadjuvant chemotherapy, treated consecutively with adjuvant t-dm1 at the various italian oncology centers.

Eligibility criteria:
inclusion criteria: * histological diagnosis of her2 positive breast cancer; * presence of invasive residual disease on t or n after neoadjuvant chemotherapy including anti-her2 agents * treatment with t-dm1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. complementary radiotherapy will be allowed as per lines guide; * availability of adequate information regarding treatment with adjuvant t-dm1 in accordance with the objectives of the study; * written informed consent for the prospective part and, if possible, for the recruited patients retrospectively exclusion criteria: * concomitant treatments with other biological agents; * absence of clinical data that allow the correct analysis of the primary and secondary objectives; * patients with a history of other malignant neoplasms; * contraindications to the use of t-dm
evaluation of prophylactic heated humidification on obstructive sleep apnea (osa) patient short term compliance to cpap therapy

Conditions: Osa Syndrome

Summary: to compare two different clinical strategies in order to evaluate the impact of prophylactic heated humidification on osa patients' compliance to cpap therapy.

to compare two different clinical strategies in order to evaluate the impact of prophylactic heated humidification on osa patients' compliance to cpap therapy.

Eligibility criteria:
inclusion criteria: * adult patient * newly diagnosed osa patients eligible to cpap therapy * signed informed consent exclusion criteria: * cpap therapy contraindications * pregnancy * patient unable to come to study follow up visits or unable to finish the study. * informed consent not signed * adults who are subject to a legal protection measure or are unable to express their consent (such as patients under guardianship and patients deprived of judicial or administrative freedom)
xlif® vs. mas®tlif for the treatment of symptomatic lumbar degenerative spondylolisthesis with or without central stenosis.

Conditions: Spondylolisthesis

Summary: the purpose of this study is to determine differences in the xlif and tlif procedures with respect to perioperative variables in adult patients with low-grade symptomatic spondylolisthesis.

the study is a prospective multi-center randomized evaluation of clinical and radiographic outcomes of two commonly used lumbar interbody fusion procedures (xlif and tlif) in adult patients with low-grade symptomatic spondylolisthesis. the study seeks to identify differences between the procedures with respect to perioperative variables.

Eligibility criteria:
inclusion criteria: - male and female patients who are at least 18 years of age; - patients who present with symptomatic grade i or ii degenerative spondylolisthesis at 1 or 2 contiguous lumbar levels between l1 and l5 and are surgical candidates for interbody lumbar fusion surgery; symptoms should include radiculopathy and/or neurogenic claudication with or without back pain; - patients who have been unresponsive to at least 6 months of conservative treatments or exhibit progressive neurological symptoms in the face of conservative treatment; - patients who understand the conditions of enrollment and are willing to sign an informed consent to participate in the study. exclusion criteria: - patients with lumbar pathologies requiring treatment at more than 2 levels; - patients who have had previous lumbar fusion surgery; - patients with lytic spondylolisthesis or a defect of the pars interarticularis; - patients with radiographic confirmation of grade iv facet joint disease or degeneration; - patients with non-contained or extruded herniated nucleus pulposus
urogenital schistosomiasis and sexually transmitted infections in madagascar

Conditions: Sexually Transmitted Infections; Schistosoma Haematobium

Summary: a cross-sectional study of urogenital schistosomiasis and sexually transmitted infections (sti) prevalence and associated morbidity in a rural community in madagascar. clearance of infections and resolution of morbidity were subsequently studied in two phases following systematic anti-sti and anti-schistosoma treatment, respectively.

the study was conducted in the schistosoma haematobium high-endemic sirama sugarcane plantation near the ambilobe town in the northern province of diego suarez in madagascar. a neighboring low-endemic village, mataipako, was selected a control village. participants aged 15 to 49 years old from sirama were included in the study if positive for s.haematobium egg in urine. a questionnaire addressing previous medical history and current urogenital symptoms was applied. a physical examination, including ultrasonophical (us) examination of urinary tract by transabdominal route, was undertaken. a pelvic examination, including transvaginal us was performed in women. in men, the prostate and the seminal vesicles were examined by transrectal us. the following sexually transmitted infections (sti) were systematically assessed: * neisseria gonorrheae * chlamydia trachomatis * mycoplasma genitalium * trichomonas * treponema pallidum * herpes simplex 1 and 2 after baseline assessment, all participants (and partners) were systematically treated with an anti-sti regimen according to the existing guidelines by the ministry of health in madagascar. re-assessment by questionnaire, physical examination and sampling for stis was undertaken 4 weeks later followed by systematic praziquantel treatment to general community, including study participants. a final follow-up study following the baseline protocol was conducted 5 months later.

Eligibility criteria:
inclusion criteria: * adults * positive schistosoma haematobium egg excretion in urine * signed written consensus exclusion criteria: * children * negative schistosoma haematobium egg excretion in urine

Keywords: sexually transmitted infections urogenital schistosomiasis schistosoma haematobium reproductive health pelvic examination ultrasonography questionnaire madagascar
real-life data from diabetic patients on closed-loop pumps

Conditions: Type 1 Diabetes

Summary: to evaluate, in real life, the effect of closed-loop devices on the improvement of glycemic control in diabetic patients managed in the endocrinology departments of secondary care hospitals.

in recent years, closed-loop insulin delivery have been developed to deliver real-time glucose-responsive insulin to people with type 1 diabetes. their use has been validated in clinical trials, but international investigative centers participating in clinical trials are not always representative of secondary care centers, and the patients they manage are also different. the eligibility criteria for participants in clinical trials are more stringent and restrictive than those of the usual patient population of diabetes/endocrinology centers. the socio-demographic characteristics of patients in clinical trials, in particular the ratio of males to females, age or ethnicity, do not necessarily reflect those observed in patients actually using the device.

Eligibility criteria:
inclusion criteria: * type i diabetic * with a closed-loop insulin pump exclusion criteria: * under legal protection order * patient or legal guardian objecting to the use of the data in the research
health-related quality of life in upper secondary schools in denmark

Conditions: Quality of Life

Summary: measuring quality of life in an upper secondary school in denmark

the child health utility 9 dimension (chu9d) is a relatively new health-related quality of life (hrqol) instrument for use in children and young people. chu9d has recently been translated and linguistic validated into danish. the objective of this study is twofold. firstly, the investigators wants to examine the feasibility of using the danish version of chu9d to assess the hrqol in young adults. secondly, the investigators wants to analyse the association of wellbeing, happiness with the school and the learning environment with the students hrqol in the northern danish region of denmark.

Eligibility criteria:
inclusion criteria: * students at the higher commercial examination (hhx) and higher technical examination (htx) at the technical college in aars. exclusion criteria: * there will be no exclusion criteria concerning diseases or conditions for these school students.

Keywords: mental health, physical health
evaluation of cardiags trimod for analysis of cardiac activity

Conditions: Murmur, Heart; Rhythm; Abnormal

Summary: the current study concerns cardiags trimod, a new non-invasive medical device for cardiac examinations. the evaluation of its effectiveness is done relative to specific standard devices.

cardiags trimod, the subject of this study, is a new medical device for rapid and early detection of some of cardiac abnormalities, easy to use by non-cardiologists and portable wherever the patient is. cardiags trimod, consisting of a device and software, allows simultaneous recording, visualization and analysis in real time of signals characteristic of cardiac function. it assists healthcare professionals by measuring characteristic time intervals of cardiac function by crossing the various signals, by detecting abnormal rhythms, and murmurs. the study aims to assess the essential requirements : the effectiveness and safety of the device. the study is a research involving the human person.cardiags trimod is a medical device with low risk. there is no identified risk for the patient.the patient sample tested consists of sick and healthy individuals. the use of cardiags trimod is part of the patient's usual consultation. the identified gold standards are ekg and echocardiography.

Eligibility criteria:
inclusion criteria: * persons suitable for receiving an echocardiogram and an electrocardiogram, * people who signed the consent form, exclusion criteria: * protected and vulnerable people, * people refusing to participate in the study,

Keywords: medical examination device connected cardiac auscultation sensors heartbeat heart sounds pulse wave electrocardiogram pathological heart sounds
impact of implementing the modified a-diva scale on successful access to a venous line on the first attempt

Conditions: Chronic Disease

Summary: peripheral venous access (pva), although commonly used, can be a difficult procedure for patients with precarious venous capital. the difficulty of insertion can lead to multiple attempts, with the consequences of pain, anxiety, delayed management and worsening of the potentially already precarious venous capital. one study assessed the risk of failure according to a score based on venous status criteria. this study first established a link between venous status criteria and the risk of failure. the criteria defined as determinants were used to establish a venous status score. the data were then repeated by analyzing the success rate as a function of the scale score. a clear link between score and risk of failure was established. it seems worthwhile to evaluate the impact of implementing this scale prior to the placement of a peripheral venous line. the hypothesis is that obtaining a score predictive of failure would modify the therapeutic attitude of the registered nurse. they would opt for techniques that would increase their chances of success. this in turn would lead to a reduction in unsuccessful attempts, which generate pain and anxiety for the patient. preserving venous capital by increasing first-attempt success is both a health issue for the patient and a guarantee of quality of care.


Eligibility criteria:
inclusion criteria: * male or female patient of legal age included in a care program requiring a vvp; * fluency in french * patient affiliated to a social security scheme; * written, signed and dated informed consent. exclusion criteria: * as the a-diva scale specifies a search for venous access to the upper limb, any patient without an upper limb or with a condition that contraindicates vvp placement in the upper limbs will be excluded; * patients treated as emergencies; * patients with a language barrier or known significant cognitive or psychiatric disorders; * patients under guardianship, curatorship, deprivation of liberty or legal protection; * pregnant or breast-feeding women.
assessing physical function in sickle cell patients taking voxelotor

Conditions: Sickle Cell Disease

Summary: voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. there have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (scd) patients, but there are few published reports on the effects of treatment on physical function in patients with scd. the hypothesis to be tested is that anemic scd patients will have improvements in performance after 6 months of voxelotor treatment.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, 4. aged 18-65 years 5. diagnosis of sickle cell disease with hbss, hbsc, hbs-beta thalassemia genotypes 6. hemoglobin level of 6 g/dl - 10.5 g/dl 7. between 0 and 10 vaso-occlusive (voc) episodes in previous 12 months 8. ability to take oral medication and be willing to adhere to the voxelotor regimen 9. for females of reproductive potential, they will be educated to avoid pregnancy during study period and for one month after due to limited data surrounding pregnancy and voxelotor 10. for males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner 11. agreement to adhere to lifestyle considerations (see section 5.3) throughout study duration exclusion criteria: 1. hemoglobin results \ 10.5 g/dl 2. patients receiving hydroxyurea who have had a dose change within the prior 3 months 3. females who are breastfeeding or pregnant 4. patients who are receiving regularly scheduled blood (rbc) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) within 30 days of 6mwt 5. any form of hepatic dysfunction as demonstrated by alanine aminotransferase (alt) \>4 × uln or child-pugh class c 6. acute kidney injury or chronic renal disease with estimated glomerular filtration rate\<30ml/min/1.73 m2 7. current or previous diagnosis of malignancy within the last two years excluding local therapy for non-melanoma skin malignancy 8. unstable cardiopulmonary disease within the last 6 months prior to study enrollment 9. any conditions including behavioral or medical that in the opinion of the investigator, may negatively impact informed consent, participation and study interpretation 10. current use of commercially available voxelotor 11. prior hypersensitivity to voxelotor or its excipients 12. patients with baseline gait and other physical impairments that would limit 6mwt and other functional assessment at discretion of the investigator 13. patients who on day of assessment present with vaso-occlusive crisis or rate their pain greater than 6 on a scale of 1-10 using the numeric rating scale will not be assessed that day and re-screened at the investigator's discretion.
are postoperative patient proms influenced by recall of preoperative scores?

Conditions: Degenerative Diseases, Spinal Cord

Summary: to evaluate whether postoperative prom scores of spine patients are influenced by memory bias


Eligibility criteria:
inclusion criteria: * all adult patients with valid preoperative prom scores submitted to spine surgery due to degenerative pathology from january 2019 to april 2020 at our center (spine unit of a neurosurgical department in a portuguese university hospital) were included in the study and received proms questionnaires with a letter of consent. exclusion criteria: * patients without valid preoperative questionnaires were excluded from the study while patients were lost to follow-up if mail questionnaires were not completed two months after proms remittance or if they had submitted incomplete or invalid answers.

Keywords: prom recall bias
mfolfoxiri compared to mfolfox6 or capeox as adjuvant chemotherapy for stage iiib or iiic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will focus on postoperative patients of stage iiib or stage iiic colorectal cancer. these patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept adjuvant chemotherapy of mfolfox6 or capeox; another group will use mfolfoxiri, they can change the regimen to mfolfox6 or capeox after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mfolfoxiri. the efficacy and safety of adjuvant chemotherapy will be compared between the two groups. disease-free survival, overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of life will be recorded.

this trial is a two-arm, open labelled, prospective, randomized phase ii studies. the postoperative stage of eligible patients was stage iiib or stage iiic. these high risk patients will be randomly assigned, in a 1:1 ratio, to receive either mfolfoxiri or mfolfox6/capeox for 6 months as adjuvant chemotherapy.

Eligibility criteria:
inclusion criteria: * age 18-75 years * ecog ps 0-1 * curative surgery (r0 resection) * ypstage iii b and ypstage iii c * no distant metastasis after surgery exclusion criteria: * any treatment before surgery including chemotherapy, radiotherapy and targeted agents. * previous or concurrent cancer that is distinct in primary site or histology from colon cancer within 5 years prior to randomization. * significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment. * heart failure grade iii/iv (nyha-classification). * unresolved toxicity higher than ctcae v.4.0 grade 1 attributed to any prior therapy/procedure. * subjects with known allergy to the study drugs or to any of its excipients. * current or recent (within 4 weeks prior to starting study treatment) treatment of another investigational drug or participation in another investigational study. * breast- feeding or pregnant women * lack of effective contraception

Keywords: colorectal cancer stage iiic stage iiib folfoxiri